[go: up one dir, main page]

AU2001266019A1 - 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives - Google Patents

2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives

Info

Publication number
AU2001266019A1
AU2001266019A1 AU2001266019A AU6601901A AU2001266019A1 AU 2001266019 A1 AU2001266019 A1 AU 2001266019A1 AU 2001266019 A AU2001266019 A AU 2001266019A AU 6601901 A AU6601901 A AU 6601901A AU 2001266019 A1 AU2001266019 A1 AU 2001266019A1
Authority
AU
Australia
Prior art keywords
amino
leucyl
tert
hydroxy
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266019A
Inventor
Pascal Furet
Carlos Garcia-Echeverria
Patricia Imbach
Marc Lang
Johann Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001266019A1 publication Critical patent/AU2001266019A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compounds of formula I wherein the substituents and symbols are defined as indicated in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
AU2001266019A 2000-05-25 2001-05-23 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives Abandoned AU2001266019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0012795.1A GB0012795D0 (en) 2000-05-25 2000-05-25 Organic compounds
GB0012795 2000-05-25
PCT/EP2001/005952 WO2001089282A2 (en) 2000-05-25 2001-05-23 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives

Publications (1)

Publication Number Publication Date
AU2001266019A1 true AU2001266019A1 (en) 2001-12-03

Family

ID=9892401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266019A Abandoned AU2001266019A1 (en) 2000-05-25 2001-05-23 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives

Country Status (11)

Country Link
US (2) US20030166572A1 (en)
EP (1) EP1290012B1 (en)
JP (1) JP2003533541A (en)
AT (1) ATE325809T1 (en)
AU (1) AU2001266019A1 (en)
CA (1) CA2405871A1 (en)
DE (1) DE60119514T2 (en)
ES (1) ES2261422T3 (en)
GB (1) GB0012795D0 (en)
PT (1) PT1290012E (en)
WO (1) WO2001089282A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050609A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
EP1865950B1 (en) 2005-04-07 2013-08-28 Centre National de la Recherche Scientifique Compounds useful as modulators of the proteasome activity
KR20100126441A (en) * 2008-02-28 2010-12-01 노파르티스 아게 Combination comprising cannabinoid receptor binding compound and opioids
US20120190565A1 (en) 2009-02-20 2012-07-26 Pangea Biosciences, Inc. Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm
US10085987B2 (en) 2012-01-27 2018-10-02 Thomas Jefferson University MCT protein inhibitor-related prognostic and therapeutic methods
EP2986290A4 (en) 2013-04-19 2017-01-04 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
IL311042A (en) * 2018-05-29 2024-04-01 Omeros Corp Masp-2 inhibitors and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538997A (en) * 1993-03-12 1996-07-23 Sandoz Ltd. 2,4-diamino-3-hydroxycarboxylic acid derivatives
EP0982317A1 (en) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
JP2002543058A (en) * 1999-04-27 2002-12-17 ノバルティス アクチエンゲゼルシャフト Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors

Also Published As

Publication number Publication date
US20030166572A1 (en) 2003-09-04
US20060205673A1 (en) 2006-09-14
PT1290012E (en) 2006-09-29
DE60119514T2 (en) 2006-10-05
WO2001089282A2 (en) 2001-11-29
WO2001089282A3 (en) 2002-05-10
JP2003533541A (en) 2003-11-11
CA2405871A1 (en) 2001-11-29
ES2261422T3 (en) 2006-11-16
ATE325809T1 (en) 2006-06-15
GB0012795D0 (en) 2000-07-19
EP1290012B1 (en) 2006-05-10
EP1290012A2 (en) 2003-03-12
DE60119514D1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MXPA04000577A (en) Dolastatin 10 derivatives.
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
PT1416935E (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0114286D0 (en) Nucleoside Derivatives
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA02007942A (en) Pyrrolopyrimidinone derivatives, process of preparation and use.
ATE245152T1 (en) DIOXOCYCLOPENTYLHYDROXAMIC ACID
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
TW200510392A (en) Chemical compounds
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
MXPA04004601A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments.
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
CY1108871T1 (en) Substituted Amino-Furan-2-yl-Acetic Acid and Amino-Thien-2-Acetic Acid Derivatives and Their Use for Home Therapy
WO2004100865A3 (en) New benzimidazole derivatives
YU87202A (en) Arylmethylamine derivatives for use as tryptase inhibitors
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
TW200505452A (en) Chemical compounds
SE9804212D0 (en) Compounds
MXPA05010020A (en) Oxamide derivatives useful as raf-kinase inhibitors.
WO2004087700A8 (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
AU2001266019A1 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
TW200504051A (en) Novel acridine derivatives and their use as medicaments